Market Place
Sourcing Support
MiNA Therapeutics Sickle Cell Data Presented at ASH Annual Meeting
07 Dec 2024 //
BUSINESSWIRE
NS Pharma Announces Research Alliance with MiNA Therapeutics
04 Apr 2024 //
PR NEWSWIRE
MiNA Collaboration with Nippon to Develop RNAa Therapeutics Targeting
04 Apr 2024 //
BUSINESSWIRE
Japan`s NS Pharma & UK-based MiNA Therapeutics lay focus on rare diseases
04 Apr 2024 //
BIOSPECTRUM ASIA
MiNA Therapeutics Presents New Data for its HbF Program
24 Jan 2024 //
BUSINESSWIRE
MiNA Therapeutics Highlights Preclinical Research on RNAa Therapeutics Presented
25 Oct 2023 //
BUSINESSWIRE
MiNA Therapeutics Presents Late-Breaking Positive Phase 1b Data for MTL-CEBPA
14 Apr 2023 //
BUSINESSWIRE
MiNA Therapeutics Presents Proof of Mechanism Data on MTL-STING
11 Apr 2022 //
BUSINESSWIRE
Dosing Begins in Randomised Phase 2 Clinical Trial of MTL-CEBPA
25 Jan 2022 //
BUSINESSWIRE
MiNA Therapeutics Appoints Two Independent Directors
21 Dec 2021 //
BIOSPACE
MiNA Therapeutics Announces Equity Investment From Lilly
06 Jul 2021 //
BUSINESSWIRE
Eli Lilly and MiNA Therapeutics enter saRNA-based drug research deal
25 May 2021 //
PHARMACEUTICAL-TECHNOLOGY
Lilly enlists a long-incubating RNA upstart in new $1.25B partnership
12 May 2021 //
ENDPTS
MiNA Therapeutics Presents Translational Data at AACR Supporting MTL-CEBPA
09 Apr 2021 //
BIOSPACE
Servier, MiNA team up to develop small-activating RNAs for neurological diseases
22 Jan 2021 //
PRESS RELEASE
Once laser-focused on liver, MiNA takes swing at neurology Servier`s backing
21 Jan 2021 //
ENDPTS
Servier and MiNA Therapeutics Enter Collaboration in Neurological Diseases
20 Jan 2021 //
BUSINESSWIRE
MiNA Therapeutics Appoints Robin Wright as Chief Financial Officer
04 Jan 2021 //
BUSINESSWIRE
MiNA Therapeutics Secures £23 Million Series A Financing
10 Sep 2020 //
BUSINESSNEWSWIRE
MiNA Therapeutics Presents Top Line Results from Phase Ib Study of MTL?CEBPA
28 May 2020 //
BUSINESSWIRE
MiNA Therapeutics Announces Publication of Phase I Liver Cancer Data
26 May 2020 //
BUSINESSWIRE
MiNA Announces Initiation of Phase I Clinical Study of MTL?CEBPA in Combination
03 Mar 2020 //
BUSINESSWIRE
MiNA Therapeutics Announces Initiation of Phase I Clinical Study of MTL?CEBPA
03 Mar 2020 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.